Drugs / PRS-080#022-DP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02340572 | Nov 2014 → Jul 2015 | — | Pieris Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02754167 | Jun 2016 → Feb 2017 | anemia due to chronic disorder | Pieris Pharmaceuticals GmbH | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03325621 Comparator | Sep 2017 → Mar 2019 | anemia due to chronic disorder | Pieris Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRS-080#022-DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03325621 ↗ |
| Action | Inhibit | “hepcidin antagonist” NCT02340572 ↗ |
| Route | Intravenous | “Study drug will be administered as i.v. infusion on Day 1.” NCT02340572 ↗ |